SDGRSchrödinger, Inc.
Price
+40%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth steady, the market undecided.
We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2025, all of the top 20 pharmaceutical companies, measured by 2024 revenue, which we refer to as our top 20 pharma industry cohort, licensed our solutions, accounting for $73.7 million, or 37%, of our software revenue and $80.8 million, or 41%, of our annual contract value, or ACV, in 2025.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Schrödinger, Inc. (SDGR) reported revenue of $59M in Q2 2026 (quarter ended Jun 30, 2026), up 7.5% from the same quarter a year earlier. That came with a gross margin of 55% and net income of $6.0M (10% of revenue). For the full year FY2025, revenue was $256M (+23% year on year) and net income −$103M. Its largest product in Q2 2026 was Drug Discovery at $23M, 40% of the disclosed total, ahead of Hosted Software at 26%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Schrödinger Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 23, 2026At the 2026 Annual Meeting of Stockholders of Schrödinger, Inc. (the “Company”) held on June 22, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2026 Plan Amendment”) to the Schrödinger, Inc. 2022 Equity Incentive Plan, as amended (the “2022 Equity Incentive Plan”)Director or officer change · Form 8-K
- Jun 8, 2026On June 5, 2026, following the previously disclosed separation of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing of Schrödinger, Inc. (the “Company”), the Company entered into a transition, separation and release of claims agreement (the “Separation Agreement”) with Mr. Aklian …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $57.4MThe company’s own SEC segment disclosure.
- Drug Discovery$23.0M40%
- Hosted Software$15.2M26%
- Drug Discovery Services$8.8M15%
- Contribution$3.4M6%
- Professional Services$3.2M6%
- Software Contribution$2.9M5%
- Other (3)$941.0K2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Health Information Services
Ranks #15 of 20 by RyuScore